Latest Insider Transactions at Bio Techne Corp (TECH)
This section provides a real-time view of insider transactions for Bio Techne Corp (TECH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIO-TECHNE Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIO-TECHNE Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 07
2022
|
John L Higgins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+15.14%
|
$66,000
$66.9 P/Share
|
|
May 10
2022
|
Robert V Baumgartner Director |
BUY
Open market or private purchase
|
Direct |
300
+2.88%
|
$105,600
$352.55 P/Share
|
|
Feb 08
2022
|
Kim Kelderman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,989
+50.0%
|
$298,350
$150.78 P/Share
|
|
Feb 01
2022
|
William Geist PRESIDENT, PROTEIN SCIENCES |
BUY
Grant, award, or other acquisition
|
Direct |
2,490
+50.0%
|
-
|
|
Jan 28
2022
|
Charles R. Kummeth Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,737
+0.44%
|
$199,755
$115.82 P/Share
|
|
Nov 19
2021
|
Kim Kelderman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
500
-60.0%
|
$252,000
$504.77 P/Share
|
|
Nov 19
2021
|
Kim Kelderman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+50.0%
|
$75,000
$150.78 P/Share
|
|
Nov 16
2021
|
Norman David Eansor President-Protein Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
799
+27.4%
|
$99,875
$125.05 P/Share
|
|
Nov 12
2021
|
Norman David Eansor President-Protein Sciences |
SELL
Open market or private sale
|
Direct |
27,159
-21.45%
|
$13,688,136
$504.35 P/Share
|
|
Nov 12
2021
|
Norman David Eansor President-Protein Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
27,159
+48.82%
|
$3,394,875
$125.05 P/Share
|
|
Nov 02
2021
|
James Hippel CFO |
SELL
Open market or private sale
|
Direct |
200
-1.83%
|
$105,000
$525.1 P/Share
|
|
Nov 02
2021
|
James Hippel CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+1.79%
|
$25,000
$125.05 P/Share
|
|
Nov 01
2021
|
James Hippel CFO |
SELL
Open market or private sale
|
Direct |
8,822
-13.79%
|
$4,649,194
$527.04 P/Share
|
|
Nov 01
2021
|
James Hippel CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,822
+31.06%
|
$1,102,750
$125.05 P/Share
|
|
Oct 29
2021
|
James Hippel CFO |
SELL
Open market or private sale
|
Direct |
662
-5.8%
|
$347,550
$525.23 P/Share
|
|
Oct 29
2021
|
James Hippel CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
662
+5.48%
|
$82,750
$125.05 P/Share
|
|
Oct 28
2021
|
Alpna Seth Director |
BUY
Grant, award, or other acquisition
|
Direct |
194
+7.68%
|
-
|
|
Oct 28
2021
|
James Hippel CFO |
SELL
Open market or private sale
|
Direct |
100
-0.92%
|
$52,500
$525.18 P/Share
|
|
Oct 28
2021
|
Julie L Bushman Director |
BUY
Grant, award, or other acquisition
|
Direct |
194
+22.35%
|
-
|
|
Oct 28
2021
|
Rupert Vessey Director |
BUY
Grant, award, or other acquisition
|
Direct |
194
+13.65%
|
-
|
|
Oct 28
2021
|
Joseph D Keegan Director |
BUY
Grant, award, or other acquisition
|
Direct |
194
+7.68%
|
-
|
|
Oct 28
2021
|
Roeland Nusse Director |
BUY
Grant, award, or other acquisition
|
Direct |
194
+2.71%
|
-
|
|
Oct 28
2021
|
John L Higgins Director |
BUY
Grant, award, or other acquisition
|
Direct |
194
+4.04%
|
-
|
|
Oct 28
2021
|
Randolph C Steer Director |
BUY
Grant, award, or other acquisition
|
Direct |
194
+3.53%
|
-
|
|
Oct 28
2021
|
Robert V Baumgartner Director |
BUY
Grant, award, or other acquisition
|
Direct |
194
+1.94%
|
-
|
|
Oct 26
2021
|
Brenda S. Furlow SVP - GENERAL COUNSEL |
BUY
Bona fide gift
|
Indirect |
2,660
+50.0%
|
-
|
|
Oct 26
2021
|
Brenda S. Furlow SVP - GENERAL COUNSEL |
SELL
Bona fide gift
|
Direct |
2,660
-19.3%
|
-
|
|
Sep 22
2021
|
Kim Kelderman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
822
-100.0%
|
$434,838
$529.04 P/Share
|
|
Sep 07
2021
|
Randolph C Steer Director |
SELL
Open market or private sale
|
Direct |
8,000
-25.36%
|
$4,080,000
$510.34 P/Share
|
|
Sep 07
2021
|
Randolph C Steer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+26.94%
|
$712,000
$89.58 P/Share
|
|
Sep 02
2021
|
Brenda S. Furlow SVP - GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
6,871
-26.84%
|
$3,504,210
$510.25 P/Share
|
|
Sep 02
2021
|
Brenda S. Furlow SVP - GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
6,871
+32.16%
|
$858,875
$125.05 P/Share
|
|
Sep 02
2021
|
James Hippel CFO |
SELL
Open market or private sale
|
Direct |
10,000
-23.99%
|
$5,080,000
$508.2 P/Share
|
|
Sep 02
2021
|
James Hippel CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+32.41%
|
$1,060,000
$106.59 P/Share
|
|
Sep 02
2021
|
Charles R. Kummeth Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
42,005
-17.6%
|
$21,422,550
$510.78 P/Share
|
|
Sep 02
2021
|
Charles R. Kummeth Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
73,492
+23.55%
|
$7,937,136
$108.49 P/Share
|
|
Aug 31
2021
|
Brenda S. Furlow SVP - GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
5,000
-14.76%
|
$2,520,000
$504.87 P/Share
|
|
Aug 31
2021
|
Brenda S. Furlow SVP - GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+28.38%
|
$625,000
$125.05 P/Share
|
|
Aug 31
2021
|
Norman David Eansor President-Protein Sciences |
SELL
Open market or private sale
|
Direct |
1,538
-53.85%
|
$773,614
$503.07 P/Share
|
|
Aug 23
2021
|
Robert V Baumgartner Director |
SELL
Open market or private sale
|
Direct |
4,000
-5.55%
|
$1,940,000
$485.27 P/Share
|
|
Aug 23
2021
|
Robert V Baumgartner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+22.71%
|
$348,000
$87.39 P/Share
|
|
Aug 23
2021
|
Roeland Nusse Director |
SELL
Open market or private sale
|
Direct |
4,000
-37.16%
|
$1,924,000
$481.52 P/Share
|
|
Aug 23
2021
|
Roeland Nusse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+27.09%
|
$280,000
$70.35 P/Share
|
|
Aug 19
2021
|
Brenda S. Furlow SVP - GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
3,538
-11.81%
|
$1,677,012
$474.08 P/Share
|
|
Aug 19
2021
|
Brenda S. Furlow SVP - GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
4,337
+16.07%
|
$498,755
$115.82 P/Share
|
|
Aug 11
2021
|
Charles R. Kummeth Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
921
+0.55%
|
$99,468
$108.49 P/Share
|
|
Aug 09
2021
|
James Hippel CFO |
SELL
Open market or private sale
|
Direct |
10,000
-7.51%
|
$4,800,000
$480.97 P/Share
|
|
Aug 09
2021
|
James Hippel CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+32.41%
|
$1,060,000
$106.59 P/Share
|
|
Aug 08
2021
|
Norman David Eansor President-Protein Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
999
-25.91%
|
$480,519
$481.82 P/Share
|
|
Aug 08
2021
|
Norman David Eansor President-Protein Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
2,537
+39.69%
|
-
|